Twist Bioscience Corporation (TWST) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 71.86M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 66.47M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -144.98M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $71.86M | (m) | $66.47M | $-144.98M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $71.89M | (m) | $64.35M | $-138.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $76.11M | (m) | $65.74M | $-134.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $80.28M | (m) | $64.46M | $-136.26M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $84.41M | (m) | $60.72M | $-142.37M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $88.83M | (m) | $58.40M | $-201.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $89.06M | (m) | $51.90M | $-208.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $90.85M | (m) | $50.92M | $-220.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $93.46M | (m) | $50.33M | $-234.90M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $95.52M | (m) | $47.19M | $-206.76M | $2.00K | (m) | (m) | -103379.00× | Reported |
| 2023-12-31 | $98.75M | (m) | $43.62M | $-219.51M | $4.00K | (m) | (m) | -54876.50× | Reported |
| 2023-09-30 | $106.89M | (m) | $30.28M | $-217.16M | $5.00K | (m) | (m) | -43431.80× | Reported |
| 2023-06-30 | $112.75M | (m) | $37.58M | $-223.92M | $30.00K | (m) | (m) | -7463.93× | Reported |
| 2023-03-31 | $125.07M | (m) | $47.02M | $-224.30M | $29.00K | (m) | (m) | -7734.52× | Reported |
| 2022-12-31 | $128.92M | (m) | $59.23M | $-223.47M | $55.00K | (m) | (m) | -4063.02× | Reported |
| 2022-09-30 | $120.31M | (m) | $79.66M | $-234.78M | $80.00K | (m) | (m) | -2934.70× | Reported |
| 2022-06-30 | $110.14M | (m) | $69.86M | $-217.72M | $137.00K | (m) | (m) | -1589.17× | Reported |
| 2022-03-31 | $93.14M | (m) | $59.00M | $-198.67M | $208.00K | (m) | (m) | -955.14× | Reported |
| 2021-12-31 | $77.70M | (m) | $48.08M | $-175.87M | $275.00K | (m) | (m) | -639.54× | Reported |
| 2021-09-30 | $69.07M | (m) | $37.00M | $-152.73M | $367.00K | (m) | (m) | -416.15× | Reported |
| 2021-06-30 | $61.27M | (m) | $32.88M | $-136.88M | $427.00K | (m) | (m) | -320.57× | Reported |
| 2021-03-31 | $51.87M | (m) | $27.78M | $-122.96M | $537.00K | (m) | (m) | -228.98× | Reported |
| 2020-12-31 | $46.71M | (m) | $20.42M | $-117.04M | $657.00K | (m) | (m) | -178.15× | Reported |
| 2020-09-30 | $43.01M | (m) | $17.10M | $-140.08M | $787.00K | (m) | (m) | -177.99× | Reported |
| 2020-06-30 | $41.87M | (m) | $15.33M | $-147.68M | $931.00K | (m) | (m) | -158.63× | Reported |
| 2020-03-31 | $40.43M | (m) | $14.29M | $-147.61M | $1.07M | (m) | (m) | -138.08× | Reported |
| 2019-12-31 | $38.71M | (m) | $13.00M | $-141.78M | $1.19M | (m) | (m) | -118.75× | Reported |
| 2019-09-30 | $35.68M | (m) | $11.17M | $-108.85M | $1.29M | (m) | (m) | -84.12× | Reported |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $20.35M | (m) | $2.96M | $-70.56M | $1.31M | (m) | (m) | -53.74× | Reported |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $19.17M | (m) | $1.89M | $-58.48M | $905.00K | (m) | (m) | -64.62× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |